Literature DB >> 8117601

Multistep transformation in low-grade lymphoproliferative diseases.

C U Ludwig1, M Gencik, R Shipman.   

Abstract

BACKGROUND: Carcinogenesis, the formation of solid tumors, is now widely accepted to represent a multistep process. Several genetic events, activation of proto-oncogenes and inactivation of tumor suppressor genes, are involved.
DESIGN: Review of the literature for evidence that the concept of multistep transformation has relevance also for the formation of low-grade lymphoproliferative diseases. RESULTS AND
CONCLUSION: The common translocations in low-grade lymphoid tumors are probably early events, predominantly involved in the activation of oncogenes, leading to growth stimulation or prolonged cell survival. As a result 'monoclonal lymphoproliferative disorders of undetermined significance (MLDUS)' occur, undetermined, because some translocations may not always led to tumor formation. For progression to full malignancy, additional genetic events are required besides sequential selection of variant subpopulations within the neoplastic clone. Recent data indicate that mutations and deletions of putative tumor suppressor genes, including the P53 and retinoblastoma genes, are also involved in the progression of lymphoproliferative disorders. A list of lymphoproliferative diseases stressing this concept of multistep transformation is presented in this article.

Entities:  

Mesh:

Year:  1993        PMID: 8117601     DOI: 10.1093/oxfordjournals.annonc.a058387

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  2 in total

1.  Reactive and neoplastic lymphocytes in human bone marrow: morphological, immunohistological, and molecular biological investigations on biopsy specimens.

Authors:  S M Kröber; H P Horny; A Greschniok; E Kaiserling
Journal:  J Clin Pathol       Date:  1999-07       Impact factor: 3.411

2.  Clonal B cell populations in a minority of patients with Hashimoto's thyroiditis.

Authors:  A Saxena; E C Alport; O Moshynska; R Kanthan; M A Boctor
Journal:  J Clin Pathol       Date:  2004-12       Impact factor: 3.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.